Clinical trial: the safety and short‐term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease

Aliment Pharmacol Ther 31 , 387–395

Summary

Background The cholera toxin B subunit ameliorates experimentally induced colitis in mice. In humans, cholera toxin B subunit has never been tested in the treatment of Crohn’s disease (CD). Aim To evaluate the safety and efficacy of treatment with recombinant cholera toxin B subunit of patients with CD. Methods An open‐label, multicentre, nonrandomized trial including 15 patients with mild/moderate CD. Patients received an oral solution of 5 mg recombinant cholera toxin B subunit three times weekly for 2 weeks. Reduction in CD Activity Index (CDAI) with >100 between baseline and days 15, 29, 42 and 70 defined clinical response. Patients with CDAI score ≤150 were defined as being in remission. Results A significant decrease in CDAI score was observed. Response rates were 40% in the full analysis set and 42% in the per protocol analysis. Two patients receiving adjuvant treatment after day 29 were excluded, after which 40% were in remission at 4 weeks and 30% at 8 weeks post‐treatment. Mild side effects (arthralgia, headache and pruritus) were seen in 33% of patients. Conclusions Treatment with recombinant cholera toxin B subunit was safe. Approximately 40% of patients with active CD responded to treatment. Randomized studies are needed to establish the clinical efficacy of recombinant cholera toxin B subunit.